“Right therapy to prevent organ rejection”
Cyonse (Tacrolimus) is an immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system and to lower the risk of organ rejection. The Cyonse (Tacrolimus) belong to drug class called calcineurin inhibitor.. It has similar immunosuppressive properties to cyclosporine, but is much more potent. Immunosuppression with Tacrolimus (Cyonse) was associated with a significantly lower rate of acute rejection compared with cyclosporine-based Immunosuppression (30.7% vs 46.4%) in one study. Long term outcome has not been improved to the same extent. Tacrolimus is normally prescribed as part of a post-transplant cocktail including steroids, mycophenolate and IL-2 receptor inhibitors
Cyonse (Tacrolimus) is an immunosuppressive drug used mainly after allogeneic organ transplant to lower the risk of organ rejection. Cyonse (Tacrolimus) is indicated for use in kidney, Liver, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. In recent years, Cyonse (Tacrolimus) has been used to suppress the inflammation associated with ulcerative colitis (UC), a form of inflammatory bowel disease.
In combination with Azathioprine: Initial dose: 0.1 mg/kg orally every 12 hours. Initiate within 24 hours of surgery, but delay until renal function has recovered. -In combination with Mycophenolate Mofetil (MMF)/interleukin-2 (IL-2) receptor antagonist: Initial dose: 0.05 mg/kg orally every 12 hours. Initiate within 24 hours of surgery, but delay until renal function has recovered.
Cyonse (Tacrolimus) is available in 1 mg capsules in 10X5’S Pack.